Medical Device recall notification (U.S. only) / field safety notice (Outside of U.S.)

In Hong Kong market, the field safety notice*advises patients and customers to take the following act:

• For patients using BiLevel PAP and CPAP devices: 
  Discontinue use of affected units and consult with physicians to determine the benefits of continuing therapy and potential risks. 
  
• For patients using life-sustaining mechanical ventilator devices: 
  DO  NOT discontinue or alter prescribed therapy, without consulting physicians to determine appropriate next steps. 

Philips is recommending that customers and patients do not use ozone-related cleaning products.

Additionally, Philips is reminding customers and patients to review the age of their BiLevel PAP and CPAP devices, as they are recommended to be replaced after five years of use.

The recall notification (U.S. only) / field safety notice (Outside of U.S.) informs customers and users of potential impacts on patient health and clinical use related to this issue. Possible health risks include exposure to degraded sound abatement foam, for example caused by unapproved cleaning methods such as ozone, and exposure to chemical emissions from the foam material.  High heat and high humidity environments may also contribute to foam degradation in certain regions.
 

Philips continues to monitor reports of potential safety issues through our post-market surveillance activities as required by medical device regulations and laws in the markets in which we operate.

In the event of exposure to degraded foam:

• The potential risks of degraded foam exposure include: Irritation (skin, eye, and respiratory tract), inflammatory response, headache, asthma, adverse effects to other organs (e.g. kidneys and liver) and toxic carcinogenic affects. 

In the event of exposure to chemical emissions:

• The potential risks of exposure due to chemical emissions from affected foam include: headache/dizziness, irritation (eyes, nose, respiratory tract, skin), hypersensitivity, nausea/vomiting, toxic and carcinogenic effects. 
  

The company will replace the current sound abatement foam with a new material that is not affected by this issue.

At this time, the company is working to address all affected devices within the scope of this correction as expeditiously as possible.  In Hong Kong market, the correction action plan has started in September, and was expected to complete within 12 months.

At this time, affected devices are on manufacturing and ship hold as the company prepares to implement the repair / replacement program for affected devices, to install new sound abatement foam material not affected by the reported issues.

The issuance of the notification is a recall in the U.S., and field safety notice in Outside of U.S., according to regulatory agency criteria.

We are treating this matter with the highest possible seriousness, and are working to addressthis issue as efficiently and thoroughly as possible.

As a result of extensive ongoing analysis, on June 14, 2021, the company issued a recall notification (U.S. only) / field safety notice (Outside of U.S.) for specific affected Continuous Positive Airway Pressure (CPAP), Bi-Level Positive Airway Pressure (BiLevel PAP) devices, and Mechanical Ventilators.

The notification informs customers and users of potential impacts on patient health and clinical use related to this issue. Possible health risks include exposure to degraded sound abatement foam, for example caused by unapproved cleaning methods such as ozone, and exposure to chemical emissions from the foam material. 

Philips is notifying customers and users of affected devices that the company will replace the current sound abatement foam with a new material that is not affected by this issue. Affected devices currently will be either replaced with a new or refurbished unit that incorporates the new material, or repaired to replace the sound abatement foam in customer units. The new material will also replace the current sound abatement foam in future products.

Philips is recommending that customers and patients do not use ozone-related cleaning products.

Additionally, Philips is reminding customers and patients to review the age of their BiLevel PAP and CPAP devices, as they are recommended to be replaced after five years of use.
 

The company has dedicated significant resources to address this issue, and has developed a comprehensive plan for this correction, and has already begun this process. This effort includes wide-scale, global ramping up of manufacturing, repair, services, supply chain and other functions to support the correction.

Philips deeply regrets the inconveniences caused by this issue, and we are dedicating significant time and resources to give affected patients and customers the service they expect and deserve as we resolve this matter as our top priority.

For more information on the recall notification (U.S. only) / field safety notice (Outside of U.S.), as well as instructions for customers, users and physicians, affected parties may contact their local Philips representative or visit www.philips.com/SRC-update.

Customers, patients, users and clinicians are instructed to follow the guidance contained in the recall notification (U.S. only) / field safety notice (International Markets).

The recall notification (U.S. only) / field safety notice (International Markets) advises patients and customers to take the following actions:

• For patients using BiLevel PAP and CPAP devices: Discontinue use of affected units and consult with physicians to determine the benefits of continuing therapy and potential risks. 
• For patients using life-sustaining mechanical ventilator devices: DO NOT discontinue or alter prescribed therapy, without consulting physicians to determine appropriate next steps. 
• Register affected devices on the recall notification (U.S. only) / field safety notice (International Markets) website, www.philips.com/SRC-update. 
  
  

The company has developed a comprehensive plan for this correction, and has already begun this process. In Hong Kong market, corrective action plan has begun in September and
is expected to complete within 12 months.

Philips is recommending that customers and patients halt use of ozone-related cleaning products, and adhere to their device Instructions for Use for approved cleaning methods.

Additionally, Philips is reminding customers and patients to review the age of their BiLevel PAP and CPAP devices, as they are typically recommended to be replaced after five years of use.

Philips deeply regrets the inconveniences caused by this issue, and we are dedicating significant time and resources to give affected patients and customers the service they expect and deserve as we resolve this matter as our top priority.

For more information on the recall notification, as well as instructions for customers, users and physicians, affected parties may contact their local Philips representative or visit www.philips.com/SRC-update. Call 877-907-7508 if you cannot visit the website or do not have internet access.

Based on Philips analysis, the root cause of this issue is related to the sound abatement foam currently used in specific identified products of the Sleep & Respiratory Care portfolio.

Philips has a robust Quality Management System and has followed our review and analysis processes to help identify and address this issue.

The products were developed according to the required standards and regulatory registrations at the time of initial release.  The Philips
Quality Management System has been upgraded to reflect alignment with updated standards. 

The foam degradation and chemical emission issues were discovered as part of our Quality Management System processes, and are being corrected in accordance with appropriate regulatory requirements.

Philips has determined that the foam may degrade under certain circumstances, influenced by factors including use of unapproved cleaning methods, such as ozone), and certain environmental conditions involving high humidity and temperature.

The environmental conditions that may be one of the causes of this issue refer to the climate and regional temperatures of the countries where the devices are used and stored.

This factor does not refer to heat and humidity generated by the device for patient use.

Users should consult with their physicians as directed in the recall notification (U.S. only) / field safety notice (Outside of U.S.).